The National Research Center on Camel (NRCC), Bikaner, initiated a
study to test camel immunology in collaboration with the Bhabha Atomic
Research Centre, Mumbai. Since camel’s immunology is unique, the
antibodies produced in its blood stream are very special and are called
nano antibodies, which have the potential to treat various diseases.
These antibodies are also expected to be used for human disease
diagnostics as well as treatment. Dr N V Patil, director, NRCC,
highlighted that the institute was working with the Bhabha Atomic
Research Centre to study the effectiveness of these antibodies on
diseases like TB and also in the diagnosis and treatment of thyroid
cancer.
![](http://biospectrumindia.ciol.com/images/content/2011/jun/Slug_r&D.jpg)
Interestingly, NRCC is also collaborating S P Medical College, Bikaner,
to develop an anti-snake venom. Dr Patil said that the nano antibodies
traverse through the animal and human body extremely fast to reach
their target, passing internal barriers like the blood-brain barrier
and placental barrier. He also pointed out that there is great prospect
in this area for developing drugs for diseases of animals and human.
Indo-German disease
R&D initiative
The Indian Council of Medical Research (ICMR) and Helmholtz Association
of German Research Centres (HGF), Germany, have launched a fellowship
under the Indo-German Science Centre for Infectious Diseases (IG-SCID)
for the financial year 2011-2012. IG-SCID is a joint initiative of HGF
and ICMR with the mission to strengthen Indo-German cooperation in the
field of infection research. The purpose of this fellowship is to
provide opportunities to Indian and German researchers to undertake
research in thematic areas of infectious diseases. Six fellowships,
each of a duration of three months, would be granted each year by both
the Indian and the German organization. Thematic research areas of
infectious diseases for training include, genetic susceptibility, viral
diseases (HIV/HCV) vaccine and anti-infectives, zoonoses & animal
models of infectious diseases. The programme will enable Indian
scientists to visit several German institutes such as, the Helmholtz
Centre for Infection Research (HZI), Braunschweig; TWINCORE Centre for
Experimental and Clinical Infection Research, Hannover; MHH Medical
University, Hannover and Helmholtz Institute for Pharmaceutical
Research Saarland (HIPS), Saarbrücken.
ICMR constitutes Vector Science Forum
The emerging and re-emerging vector borne diseases like dengue,
chikungunya, japanese encephalitis, chandipura virus, nipah viruses,
malaria, filariasis, and visceral leishmaniasis have posed a great
challenge to researchers, disease control programme planners and
implementers in the country. In this context, the Indian Council for
Medical Research (ICMR) has now constituted a ‘Vector Science Forum’ in
order to promote research on vectors and to develop a common platform
for all vector biologists, entomologists, programme people and experts
embarking upon common issues. The projects would be funded by ICMR and
will involve extensive research in selective priority areas. ICMR
expects the forum to help in the field of evaluation trials to evaluate
new insecticides, vector control tools in different vector eco-systems
and evaluation of diagnostic kits and assays for parasite detection.
Gene therapy to cure
AMD
A new in vivo study by researchers at Tufts University School of
Medicine revealed that a new gene therapy approach using a protein
called CD59, or protectin, has a lot of potential to slow the signs of
age-related macular degeneration (AMD). The team, which was led by
senior author Dr Rajendra Kumar-Singh demonstrated for the first time
that CD59 delivered by a gene therapy approach significantly reduced
the uncontrolled blood vessel growth and cell death that is typical of
AMD, which is the most common cause of blindness in the elderly.
Activation of the complement system, a part of the immune system, leads
to the generation of pores known as ‘membrane attack complex’ or MAC in
cell membranes, which leads to the killing of the cells in the back of
the eye and causes AMD. CD59 is known to block the formation of MAC.
Using an established mouse model of AMD, they found that the eyes had
62 percent less uncontrolled blood vessel growth and 52 percent less
MAC than the controls. The current standard treatment for some forms of
AMD requires an injection directly into the eye approximately every
four weeks. According to Dr Kumar-Singh, gene therapy approaches to
treat AMD are especially attractive because they will allow patients to
be treated less frequently, reducing patient discomfort and lowering
chances of infection. The study received grants from The Ellison
Foundation, the National Eye Institute, the National Institutes of
Health, the Virginia B Smith Trust, the department of ophthalmology at
TUSM, the Lions Eye Foundation and Research to Prevent Blindness.